Natus Medical Inc has closed its acquisition of Micromed Holding SAS, a global provider of neurophysiology solutions. Micromed products will be added to the Natus Neuro portfolio and developed alongside Natus technologies.
“We are thrilled to complete this deal and move forward combining the Natus and Micromed teams and product portfolios,” says Austin Noll, Natus president and leader of Natus Neuro, in a release. “Together we will be able to provide our neuroscience customers a more comprehensive product offering and unrivaled global service and support through the increased breadth and depth of our combined resources.”
Natus will grow through the addition of the complete line of Micromed solutions to comprise an even stronger portfolio of products across electroencephalography (EEG), polysomnography (PSG), electromyography (EMG), and intensive care unit (ICU) monitoring. Together the products and organizational experience will bring incremental value to customers around the world, while also providing a strong platform for new product development.
“The Micromed team is excited to bring our passion, our experience, our products and our European leadership to Natus,” says Cristiano Rizzo, general manager of Micromed, in a release. “As we expand through the extensive Natus structure, we will continue to cultivate the customer and key opinion leader relationships that we have established at Micromed over the years.”
This acquisition is the first by Natus since its de-listing from the NASDAQ in July 2022 and reflects a commitment to invest in growth. “The acquisition of Micromed is the first transaction in our acquisition roadmap to build leading companies in both neuro and sensory under the Natus umbrella,” says Thomas J. Sullivan, Natus CEO, in a release. “This is a significant milestone for Natus, our customers, and their patients.”
Photo 49636008 © Diane Picard | Dreamstime.com
